Long-Term Safety, Efficacy of Sunitinib for Gastrointestinal Tumors Confirmed

Share this content:

the Cancer Therapy Advisor take:

The long-term safety and efficacy of sunitinib in patients with advanced gastrointestinal stromal tumor (GIST) was confirmed in a large international population, according to a study published online in the journal Cancer.

In this study, the imatinib-resistant/intolerant patients were given an initial dosage of sunitinib 50 mg daily in 6-week cycles—4 weeks on treatment and 2 weeks off treatment. Tumor response was assessed using the Response Evaluation Criteria in Solid Tumors version 1.0.

Overall, the study included 1,124 patients in the intent-to-treat population, 15% of which had a baseline Eastern Cooperative Oncology Group performance status greater than or equal to 2. 

Median values for treatment duration and tumor progression were analyzed [7.0 months and 8.3 months (95% CI: 8.0, 9.4 months), respectively].  The median overall survival was found to be 16.6 months (95% CI: 14.9, 18.0 months), with 36% of patients alive at the time of analysis.

Patients that had a modified initial dosing schedule had a longer median overall survival of 23.5 months compared with patients who were strictly treated using the initial dosing schedule (OS 11.1 months).

Treatment-related grade 3 and 4 adverse events included hand-foot syndrome (11%), fatigue (9%), neutropenia (8%), hypertension (7%), thrombocytopenia (6%), and those associated with cardiac function (e.g., congestive heart failure) (≤1%). 

Radiotherapy plus temozolomide did not appear to significantly improve survival for anapestic astroc
Long-term safety and efficacy of sunitinib in patients with advanced gastrointestinal stromal tumor was confirmed.
The objectives of this study were to provide sunitinib to patients with gastrointestinal stromal tumor (GIST) who were otherwise unable to obtain it and to collect broad safety and efficacy data from a large population of patients with advanced GIST after imatinib failure.
READ FULL ARTICLE From Wiley Online Library

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs